|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
|
ES2118941T3
(es)
*
|
1992-02-21 |
1998-10-01 |
Alcon Lab Inc |
Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.
|
|
AU3722793A
(en)
*
|
1992-09-17 |
1994-04-12 |
Alcon Laboratories, Inc. |
Topical carbonic anhydrase inhibitor composition
|
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
|
CA2166722A1
(en)
*
|
1994-05-06 |
1995-11-16 |
Manoj L. Maniar |
Use of vitamin e tocopheryl derivatives in ophthalmic compositions
|
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
CA2237898A1
(en)
*
|
1995-11-17 |
1997-05-29 |
Louis Desantis Jr. |
Combination therapy for treating glaucoma
|
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
|
CH690814A5
(it)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Composizioni per uso topico contenenti polisaccaridi solfati.
|
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
AU2183900A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
|
AU2183800A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Prostaglandin e agonists for treatment of dry eye
|
|
EP1155019B1
(en)
|
1999-01-25 |
2005-12-07 |
National Jewish Medical and Research Center |
Substituted porphyrins and their therapeutic use
|
|
JP2003513046A
(ja)
|
1999-11-01 |
2003-04-08 |
アルコン，インコーポレイテッド |
フルオロキノロン抗生薬およびキサンタンガムを含有する薬学的組成物
|
|
US6255343B1
(en)
|
1999-11-09 |
2001-07-03 |
Alcon Universal Ltd. |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
|
PT1228030E
(pt)
|
1999-11-09 |
2005-08-31 |
Alcon Inc |
Derivados benzenoidicos do acido 15-hidroxieicosatetraenoico e metodos para a sua utilizacao no tratamento das perturbacoes do olho seco
|
|
AU1226001A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
|
|
US6331644B1
(en)
|
1999-11-09 |
2001-12-18 |
Alcon Universal Ltd. |
3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use
|
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
WO2001034550A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
|
DK1228032T3
(da)
|
1999-11-09 |
2004-11-01 |
Alcon Inc |
Præparater, som indeholder hydroxyicosatetraensyrederivater, og fremgangsmåder til anvendelse ved behandling af öjentörhedslidelser
|
|
BR0015402A
(pt)
|
1999-11-09 |
2002-06-25 |
Alcon Inc |
Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
|
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
ATE258791T1
(de)
|
1999-11-09 |
2004-02-15 |
Alcon Inc |
Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
|
|
DE60019322T2
(de)
|
1999-11-09 |
2005-09-08 |
Alcon Inc. |
Heteroatomunterbrochene analoge von15-hydroxyeicosatetraensäure und verfahren zu deren verwendung
|
|
DE60007547T2
(de)
|
1999-11-09 |
2004-06-17 |
Alcon, Inc. |
15-hydroxyeicosatetraensäure verwandte verbindungen und anwendungsverfahren
|
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
KR20020050240A
(ko)
|
1999-11-09 |
2002-06-26 |
구이도 콜러, 스테판 바슬러 |
하이드록시에이코사테트라에노에이트 염, 조성물 및 안구건조증 치료에서의 사용 방법
|
|
US6576663B2
(en)
|
1999-12-22 |
2003-06-10 |
Alcon, Inc. |
6-Keto prostaglandin F1α and analogs for treating dry eye
|
|
AU2001270593A1
(en)
|
2000-07-28 |
2002-02-13 |
Alcon Universal Ltd. |
Pharmaceutical compositions containing tobramycin and xanthan gum
|
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
|
US7060297B2
(en)
|
2000-11-06 |
2006-06-13 |
Alcon, Inc. |
Carrageenan viscoelastics for ocular surgery
|
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
|
ATE353667T1
(de)
|
2001-05-21 |
2007-03-15 |
Alcon Inc |
Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
|
|
BR0209965A
(pt)
|
2001-05-21 |
2004-04-06 |
Alcon Inc |
Uso de inibidores de nf-kappab para tratar distúrbios do olho seco
|
|
US20030008853A1
(en)
*
|
2001-05-21 |
2003-01-09 |
Alcon, Inc. |
Method for treating dry eye disorders
|
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
JP2005508864A
(ja)
*
|
2001-06-01 |
2005-04-07 |
ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター |
糖尿病の治療、または移植術における使用、または免疫寛容の誘導のためのオキシダントスカベンジャー
|
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
|
US6750250B1
(en)
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
CA2464736A1
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US20040019012A1
(en)
*
|
2002-02-22 |
2004-01-29 |
Singh Satish K. |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
|
|
EP1476135A1
(en)
*
|
2002-02-22 |
2004-11-17 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
|
SI1534286T1
(sl)
|
2002-07-29 |
2010-04-30 |
Rigel Pharmaceuticals Inc |
Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
|
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
|
AU2003303623A1
(en)
*
|
2002-12-20 |
2004-07-29 |
Alcon, Inc. |
Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
|
|
EP1663242B1
(en)
|
2003-08-07 |
2011-04-27 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
|
|
KR20120005052A
(ko)
*
|
2003-08-21 |
2012-01-13 |
수캄포 아게 |
안과용 조성물
|
|
WO2006034277A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc. |
Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
|
|
US7659289B2
(en)
*
|
2004-09-17 |
2010-02-09 |
Comentis, Inc. |
Hydroxyethylene-based β-secretase inhibitors and use thereof
|
|
EP1831225A2
(en)
*
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
|
NZ562314A
(en)
*
|
2005-04-08 |
2010-02-26 |
Comentis Inc |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
|
JP2009528295A
(ja)
|
2006-02-24 |
2009-08-06 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ経路の阻害のための組成物および方法
|
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
|
EP2038272B8
(en)
|
2006-06-30 |
2013-10-23 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl pdk1 inhibitors
|
|
ES2380551T3
(es)
|
2006-11-21 |
2012-05-16 |
Rigel Pharmaceuticals, Inc. |
Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
|
|
KR20080076667A
(ko)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
요변성 약학 조성물
|
|
CA2691531C
(en)
|
2007-06-22 |
2016-11-01 |
Board Of Regents,The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
|
KR20100051668A
(ko)
*
|
2007-07-26 |
2010-05-17 |
코멘티스, 인코포레이티드 |
베타-세크레타제 활성을 억제하는 이소프탈아미드 유도체
|
|
CA2699787A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Comentis, Inc. |
(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
|
|
CA2708281A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
|
BRPI0909797A2
(pt)
*
|
2008-03-07 |
2017-08-22 |
Sun Pharma Advanced Res Co Ltd |
Composição oftálmica
|
|
US11382895B2
(en)
|
2008-05-23 |
2022-07-12 |
National Jewish Health |
Methods for treating injury associated with exposure to an alkylating species
|
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
|
EP2340248B1
(en)
|
2008-09-15 |
2017-05-31 |
The Regents of The University of California |
Methods and compositions for modulating ire1, src, and abl activity
|
|
JP5815411B2
(ja)
|
2008-12-30 |
2015-11-17 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ピリミジンジアミンキナーゼ阻害剤
|
|
PL2389372T3
(pl)
|
2009-01-23 |
2016-02-29 |
Rigel Pharmaceuticals Inc |
Kompozycje i sposoby hamowania szlaku JAK
|
|
EP3620154A1
(en)
|
2009-02-06 |
2020-03-11 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
|
AU2010220061A1
(en)
*
|
2009-02-20 |
2010-09-10 |
Micro Labs Limited |
Storage stable prostaglandin product
|
|
CA2768543C
(en)
|
2009-07-28 |
2017-06-20 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
NZ598262A
(en)
|
2009-08-17 |
2014-05-30 |
Sloan Kettering Inst Cancer |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
|
WO2011029043A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Heteroaryl btk inhibitors
|
|
CA2771822C
(en)
|
2009-09-04 |
2020-08-11 |
Daniel A. Erlanson |
Bruton's tyrosine kinase inhibitors
|
|
AU2010303567B2
(en)
|
2009-10-06 |
2016-06-09 |
Millennium Pharmaceuticals, Inc |
Heterocyclic compounds useful as PDK1 inhibitors
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
EP2493465B1
(en)
|
2009-10-26 |
2014-10-22 |
Sephoris Pharmaceuticals, LLC |
Treatment of sunburn using analgesics and antihistamines
|
|
MX2012005678A
(es)
|
2009-11-16 |
2012-09-07 |
Univ California |
Enhibidores de cinasas.
|
|
WO2011072257A2
(en)
|
2009-12-10 |
2011-06-16 |
The Regents Of The University Of California |
Amyloid binding agents
|
|
CA2828833C
(en)
|
2010-03-03 |
2020-11-03 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising monoterpenes
|
|
JP6155187B2
(ja)
|
2010-03-30 |
2017-06-28 |
ヴァーセオン コーポレイション |
トロンビンの阻害剤としての多置換芳香族化合物
|
|
AU2011242562B2
(en)
|
2010-04-24 |
2016-10-13 |
Mycovia Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
KR101937495B1
(ko)
|
2010-07-28 |
2019-01-10 |
리겔 파마슈티칼스, 인크. |
Ｊａｋ 경로의 억제를 위한 조성물 및 방법
|
|
WO2012083178A1
(en)
|
2010-12-17 |
2012-06-21 |
Neo Oncology Inc. |
Methods and devices for using isoperillyl alcohol
|
|
ES2600928T3
(es)
|
2010-08-27 |
2017-02-13 |
Neonc Technologies Inc. |
Composiciones farmacéuticas que comprenden derivados de alcohol perilílico
|
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
CA2816088A1
(en)
|
2010-10-28 |
2012-05-03 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
WO2012058645A1
(en)
|
2010-10-29 |
2012-05-03 |
Biogen Idec Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
|
KR20180039185A
(ko)
|
2010-11-13 |
2018-04-17 |
이노크린 파마슈티컬즈, 인크. |
금속효소 억제제 화합물
|
|
EA201390876A1
(ru)
|
2010-12-13 |
2013-12-30 |
Вайамет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
BR112013020719B1
(pt)
|
2011-02-14 |
2018-04-17 |
Allergan, Inc. |
Composições de derivados de bimatoprost tipo éster e métodos
|
|
CA2828360A1
(en)
|
2011-02-25 |
2012-08-30 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Chrysophaentin analogs that inhibit ftsz protein
|
|
EP3682896A1
(en)
|
2011-04-28 |
2020-07-22 |
University of Southern California |
Human myeloid derived suppressor cell cancer markers
|
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
HUE048834T2
(hu)
|
2011-05-17 |
2020-08-28 |
Univ California |
Kináz inhibitorok
|
|
EA025496B1
(ru)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
|
US20140221282A1
(en)
|
2011-05-25 |
2014-08-07 |
Astrazeneca Pharmaceuticals Lp |
Long duration dual hormone conjugates
|
|
US8809378B2
(en)
|
2011-06-19 |
2014-08-19 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
CN105884743B
(zh)
|
2011-06-19 |
2019-08-06 |
威尔金制药(Nc)有限公司 |
金属酶抑制剂化合物
|
|
EA201490052A1
(ru)
|
2011-06-23 |
2014-04-30 |
Вайамет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
EP2726097A4
(en)
|
2011-07-01 |
2015-03-11 |
Univ California |
HERPES VIRUS VACCINE AND METHOD OF USE
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
WO2013063492A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
|
EP3351541A1
(en)
|
2011-12-11 |
2018-07-25 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyme inhibitor compounds
|
|
EA026209B1
(ru)
|
2012-01-20 |
2017-03-31 |
Ваймет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
NZ629898A
(en)
|
2012-03-23 |
2016-04-29 |
Oxigene Inc |
Compositions and methods for inhibition of cathepsins
|
|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
EP2858500A4
(en)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
BRUTON TYROSINE KINASE HEMMER
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
KR20200110820A
(ko)
|
2012-08-27 |
2020-09-25 |
알레간 인코포레이티드 |
베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
US9266895B2
(en)
|
2012-09-10 |
2016-02-23 |
Principia Biopharma Inc. |
Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
|
|
MX2015003874A
(es)
|
2012-09-26 |
2015-12-16 |
Univ California |
Modulacion de ire1.
|
|
CN104870452B
(zh)
|
2012-10-22 |
2018-04-13 |
希望之城 |
Etp衍生物
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
NZ710444A
(en)
|
2013-02-11 |
2020-08-28 |
Univ California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
|
BR112015023383A2
(pt)
|
2013-03-14 |
2017-07-18 |
Hope City |
compostocomposição farmacêutica; e método de modulação
|
|
JP2016519662A
(ja)
|
2013-03-14 |
2016-07-07 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｋ２ｐチャネルの調節
|
|
CA2903827C
(en)
|
2013-03-14 |
2021-08-10 |
Stefan Oscarson |
Thiosaccharide mucolytic agents
|
|
ES2791749T3
(es)
|
2013-03-15 |
2020-11-05 |
Verseon Corp |
Halogenopirazoles como inhibidores de la trombina
|
|
WO2014145986A1
(en)
|
2013-03-15 |
2014-09-18 |
Verseon, Inc. |
Multisubstituted aromatic compounds as serine protease inhibitors
|
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
CN105338985A
(zh)
|
2013-03-15 |
2016-02-17 |
阿勒根公司 |
用于增加瘦素生成的比马前列素
|
|
SMT201800538T1
(it)
|
2013-03-15 |
2019-01-11 |
Univ California |
Diesteri di fosfonato nucleosidico aciclico
|
|
JP6806562B2
(ja)
|
2013-03-15 |
2021-01-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ｅＩＦ２α経路の調節因子
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
EP2999472B1
(en)
|
2013-05-22 |
2020-07-22 |
The Regents of The University of California |
Aurora kinase inhibitors
|
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
|
AU2014290202B2
(en)
|
2013-07-15 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
|
PT3035926T
(pt)
|
2013-08-19 |
2020-09-01 |
Univ California |
Compostos e métodos para tratar um distúrbio epiléptico
|
|
CN105979941A
(zh)
|
2013-08-20 |
2016-09-28 |
希望之城 |
用于治疗癌症的hdac8抑制剂
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
HRP20181109T1
(hr)
|
2013-12-11 |
2018-11-02 |
Biogen Ma Inc. |
Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
|
|
US10280169B2
(en)
|
2013-12-11 |
2019-05-07 |
Biogen Ma Inc. |
Biaryl bruton's tyrosine kinase inhibitors
|
|
AU2014386214B2
(en)
|
2013-12-23 |
2020-05-21 |
Memorial Sloan-Kettering Cancer Center |
Methods and reagents for radiolabeling
|
|
EP2898888B8
(en)
|
2014-01-22 |
2019-06-12 |
VISUfarma B.V. |
Composition comprising iota-carrageenan against viral Conjunctivitis
|
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
|
CA2939219C
(en)
|
2014-02-11 |
2023-02-28 |
Mitokinin Llc |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
WO2015123595A1
(en)
|
2014-02-14 |
2015-08-20 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
CA2939569A1
(en)
|
2014-02-20 |
2015-11-19 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
EP4681737A3
(en)
|
2014-02-21 |
2026-03-11 |
Principia Biopharma Inc. |
Salts and solid form of a btk inhibitor
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
CN106132203B
(zh)
|
2014-03-26 |
2020-05-15 |
希望之城 |
Brca1缺陷性癌症或抗性癌症的治疗
|
|
WO2015157313A1
(en)
|
2014-04-07 |
2015-10-15 |
The Regents Of The University Of California |
Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
|
|
EA201692155A1
(ru)
|
2014-05-13 |
2017-04-28 |
Мемориал Слоун-Кеттеринг Кэнсэ Сентр |
МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
|
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
|
WO2016023036A1
(en)
|
2014-08-08 |
2016-02-11 |
The Regents Of The University Of California |
High density peptide polymers
|
|
WO2016040806A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
mTORC1 INHIBITORS
|
|
HRP20220651T1
(hr)
|
2014-09-15 |
2022-08-19 |
The Regents Of The University Of California |
Nukleotidni analozi
|
|
KR20170048410A
(ko)
|
2014-09-17 |
2017-05-08 |
베르선 코포레이션 |
세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
US10329284B2
(en)
|
2014-10-02 |
2019-06-25 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
|
US10485797B2
(en)
|
2014-12-18 |
2019-11-26 |
Principia Biopharma Inc. |
Treatment of pemphigus
|
|
EP3733696A1
(en)
|
2015-01-13 |
2020-11-04 |
City of Hope |
Ctla4-binding protein peptide-linker masks
|
|
AR103428A1
(es)
|
2015-01-16 |
2017-05-10 |
Hope City |
Anticuerpos de penetración celular
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
EP3872069A1
(en)
|
2015-02-12 |
2021-09-01 |
Neonc Technologies, Inc. |
Pharmaceutical compositions comprising perillyl alcohol derivatives
|
|
SI3261640T1
(sl)
|
2015-02-25 |
2022-10-28 |
The Regents Of The University Of California |
5HT agonisti za zdravljenje epilepsijskih motenj
|
|
AU2016224974B2
(en)
|
2015-02-27 |
2019-09-26 |
Verseon Corporation |
Substituted pyrazole compounds as serine protease inhibitors
|
|
CN107531687A
(zh)
|
2015-02-27 |
2018-01-02 |
加利福尼亚大学董事会 |
能够实现软骨复壮的小分子
|
|
KR102629269B1
(ko)
|
2015-02-27 |
2024-01-24 |
커타나 파마슈티칼스, 인크. |
Olig2 활성의 억제
|
|
WO2016161018A1
(en)
|
2015-03-30 |
2016-10-06 |
City Of Hope |
Mechanically interlocking complexes
|
|
MX382355B
(es)
|
2015-04-10 |
2025-03-13 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
|
|
EP3283462B1
(en)
|
2015-04-15 |
2020-12-02 |
Araxes Pharma LLC |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
AU2016247858B2
(en)
|
2015-04-17 |
2020-10-15 |
Ludwig Institute For Cancer Research Ltd. |
PLK4 inhibitors
|
|
JP6704000B2
(ja)
|
2015-04-24 |
2020-06-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｒｏｒ１−ｒｏｒ２結合のモジュレーター
|
|
AU2016265845B2
(en)
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
|
US10765696B2
(en)
|
2015-06-10 |
2020-09-08 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
|
WO2016201280A1
(en)
|
2015-06-10 |
2016-12-15 |
Biogen Ma Inc. |
Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
|
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
|
CA2991052A1
(en)
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2811136T3
(es)
|
2015-08-04 |
2021-03-10 |
Rigel Pharmaceuticals Inc |
Compuestos de benzazol y métodos para obtener y usar los compuestos
|
|
JP7104462B2
(ja)
|
2015-08-06 |
2022-07-21 |
シティ・オブ・ホープ |
細胞透過性タンパク質－抗体コンジュゲートおよび使用方法
|
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
|
WO2017040982A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of California |
Her3 ligands and uses thereof
|
|
WO2017041040A1
(en)
|
2015-09-04 |
2017-03-09 |
City Of Hope |
Androgen receptor antagonists
|
|
US10550070B2
(en)
|
2015-09-17 |
2020-02-04 |
City Of Hope |
PCNA inhibitors
|
|
US11253521B2
(en)
|
2015-09-25 |
2022-02-22 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3985116A1
(en)
|
2015-10-15 |
2022-04-20 |
City of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
AU2016341884B2
(en)
|
2015-10-19 |
2021-06-10 |
Board Of Regents, The University Of Texas System |
Piperazinyl norbenzomorphan compounds and methods for using the same
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
EP3364956A4
(en)
|
2015-10-23 |
2019-05-01 |
ERX Pharmaceuticals, Inc. |
ANALOG OF CELASTROL
|
|
PL3364971T3
(pl)
|
2015-10-23 |
2021-05-31 |
Sunesis Pharmaceuticals, Inc. |
Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu
|
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
|
EP3377481A1
(en)
|
2015-11-16 |
2018-09-26 |
Araxes Pharma LLC |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
TW201733621A
(zh)
|
2015-12-10 |
2017-10-01 |
世代好公司 |
細胞穿透性之花青耦合抗體
|
|
RU2730855C2
(ru)
|
2015-12-24 |
2020-08-26 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа |
Кфтр регуляторы и способы их применения
|
|
ES3066112T3
(en)
|
2015-12-24 |
2026-05-11 |
The Regents Of The Univ Of California |
Cftr regulators and methods of use thereof
|
|
WO2017117393A1
(en)
|
2015-12-30 |
2017-07-06 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
EP4643881A3
(en)
|
2016-01-05 |
2026-04-22 |
The Regents of the University of California |
Benzothiazole amphiphiles
|
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
|
WO2017161344A1
(en)
|
2016-03-17 |
2017-09-21 |
The Regants Of The University Of California |
Compositions and methods for treating parasitic diseases
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
WO2017189613A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
|
EP3448519A4
(en)
|
2016-04-29 |
2020-01-22 |
Board Of Regents, The University Of Texas System |
SIGMA RECEPTOR BINDING
|
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
HK1258717A1
(zh)
|
2016-05-12 |
2019-11-15 |
安纳考尔医药公司 |
氧杂硼杂环戊烷酯类及其用途
|
|
US10918648B2
(en)
|
2016-05-26 |
2021-02-16 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
|
EP3475263B1
(en)
|
2016-06-27 |
2022-12-28 |
Rigel Pharmaceuticals, Inc. |
2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
|
|
IL293621B2
(en)
|
2016-06-29 |
2023-09-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
|
|
WO2018013609A2
(en)
|
2016-07-11 |
2018-01-18 |
The Regents The University Of California |
Synthetic melanin nanoparticles uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
SG11201900515PA
(en)
|
2016-07-21 |
2019-02-27 |
Biogen Ma Inc |
Succinate forms and compositions of bruton's tyrosine kinase inhibitors
|
|
PL3490565T3
(pl)
|
2016-07-29 |
2022-09-26 |
Rapt Therapeutics, Inc. |
Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
|
US20190218261A1
(en)
|
2016-09-13 |
2019-07-18 |
The Jackson Laboratory |
Targeted enhanced dna demethylation
|
|
JP7088912B2
(ja)
|
2016-09-15 |
2022-06-21 |
シティ・オブ・ホープ |
ジチオｅｔｐ誘導体
|
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
ES2946001T3
(es)
|
2016-10-26 |
2023-07-11 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol amida como inhibidores de IRAK
|
|
ES2939232T3
(es)
|
2016-10-26 |
2023-04-20 |
Rigel Pharmaceuticals Inc |
Derivados de oxazol para uso como inhibidores de IRAK y método para su preparación
|
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
|
CN110267538B
(zh)
|
2016-11-30 |
2022-04-19 |
尼昂克技术公司 |
紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
|
|
EP3555077B1
(en)
|
2016-12-15 |
2023-04-19 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
EP3562487B1
(en)
|
2016-12-29 |
2023-11-29 |
Ji Xing Pharmaceuticals Hong Kong Limited |
Metalloenzyme inhibitor compounds
|
|
EP3562306B1
(en)
|
2016-12-29 |
2025-02-26 |
Ji Xing Pharmaceuticals Hong Kong Limited |
Metalloenzyme inhibitor compounds
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
|
KR20200019228A
(ko)
|
2017-06-21 |
2020-02-21 |
미토키닌, 인크. |
신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
|
|
CN111032642B
(zh)
|
2017-06-29 |
2023-07-18 |
里格尔药品股份有限公司 |
激酶抑制剂及制造和使用方法
|
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
WO2019067498A2
(en)
|
2017-09-29 |
2019-04-04 |
Genentech, Inc. |
PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE
|
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
|
WO2019074962A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES
|
|
WO2019079819A1
(en)
|
2017-10-20 |
2019-04-25 |
City Of Hope |
COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
|
|
WO2019090078A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
SG11202004009TA
(en)
|
2017-11-02 |
2020-05-28 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
AU2018358157B2
(en)
|
2017-11-02 |
2023-03-09 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
|
EP3704089B1
(en)
|
2017-11-02 |
2023-07-19 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
CA3080948A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
JP2021501785A
(ja)
|
2017-11-02 |
2021-01-21 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
|
RU2020118594A
(ru)
|
2017-11-06 |
2021-12-09 |
Рапт Терапьютикс, Инк. |
Противораковые агенты
|
|
WO2019113311A1
(en)
|
2017-12-06 |
2019-06-13 |
Ludwig Institute For Cancer Research Ltd |
Methods of treating cancer with plk4 inhibitors
|
|
MA51052A
(fr)
|
2017-12-07 |
2021-04-21 |
Amplyx Pharmaceuticals Inc |
Agents antifongiques dérivés de pyridine substitués par un hétérocycle
|
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
RS66124B1
(sr)
|
2017-12-15 |
2024-11-29 |
Biohaven Therapeutics Ltd |
Derivati 5-(2-(2,5-difluorofenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina i srodna jedinjenja kao inhibitori trk kinaze za lečenje kancera
|
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
|
WO2019143730A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
EP3740207A4
(en)
|
2018-01-16 |
2021-10-13 |
Syros Pharmaceuticals, Inc. |
CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS
|
|
AU2019212478C1
(en)
|
2018-01-26 |
2023-11-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
BR112020016074A2
(pt)
|
2018-02-08 |
2020-12-08 |
Neonc Technologies, Inc |
Métodos de permeabilização da barreira hematoencefálica
|
|
WO2019178129A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
CN112423747A
(zh)
|
2018-04-27 |
2021-02-26 |
云杉生物科学公司 |
用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
|
|
CA3098698A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mtor inhibitors
|
|
CN118978535A
(zh)
|
2018-05-01 |
2024-11-19 |
锐新医药公司 |
作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
|
|
KR102823195B1
(ko)
|
2018-05-03 |
2025-06-20 |
리겔 파마슈티칼스, 인크. |
Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
|
|
PT3788044T
(pt)
|
2018-05-03 |
2023-08-31 |
Rigel Pharmaceuticals Inc |
Compostos inibidores de rip1 e métodos para preparar e usar os mesmos
|
|
WO2019213611A1
(en)
|
2018-05-04 |
2019-11-07 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
|
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
|
EP3801501A4
(en)
|
2018-06-06 |
2022-03-23 |
The Regents of the University of California |
ESTROGEN RECEPTOR INHIBITORS AND THEIR USES
|
|
KR102533477B1
(ko)
|
2018-06-21 |
2023-05-18 |
칼리코 라이프 사이언시스 엘엘씨 |
단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
|
|
US11771688B2
(en)
|
2018-06-25 |
2023-10-03 |
Amplyx Pharmaceuticals, Inc. |
Pyridine derivatives substituted by heterocyclic ring and amino group
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
|
CN112996527B
(zh)
|
2018-08-31 |
2025-02-21 |
巴斯利尔药物阿尔施维尔国际股份公司 |
用于治疗真菌感染的化合物和方法
|
|
US12187762B2
(en)
|
2018-09-10 |
2025-01-07 |
The Regents Of The University Of California |
Dithiolsaccharide mucolytic agents and uses thereof
|
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
EP3856742B1
(en)
|
2018-11-01 |
2024-10-02 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
|
|
WO2020092845A1
(en)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
WO2020118683A1
(en)
|
2018-12-14 |
2020-06-18 |
Lynk Pharmaceuticals Co. Ltd. |
Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
|
|
CN114269383A
(zh)
|
2019-01-08 |
2022-04-01 |
菲斯生物制药公司 |
金属酶抑制剂化合物
|
|
AU2020234712B2
(en)
|
2019-03-14 |
2025-12-04 |
Abbvie Inc. |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
|
PE20220572A1
(es)
|
2019-04-30 |
2022-04-20 |
Calico Life Sciences Llc |
Moduladores de la via integrada del estres
|
|
WO2020232274A1
(en)
|
2019-05-15 |
2020-11-19 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
WO2020252487A1
(en)
|
2019-06-14 |
2020-12-17 |
Children's Hospital Medical Center |
Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
|
|
BR112022001418A2
(pt)
|
2019-08-08 |
2022-06-07 |
Rigel Pharmaceuticals Inc |
Compostos e método para tratar a síndrome de liberação de citocinas
|
|
WO2021030526A1
(en)
|
2019-08-14 |
2021-02-18 |
Rigel Pharmaceuticals, Inc. |
Method of blocking or ameliorating cytokine release syndrome
|
|
PH12022550466A1
(en)
|
2019-08-30 |
2023-03-06 |
Rigel Pharmaceuticals Inc |
Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
|
|
CR20220075A
(es)
|
2019-09-06 |
2022-07-14 |
Rigel Pharmaceuticals Inc |
Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
|
|
EP4025574B1
(en)
|
2019-09-06 |
2025-05-07 |
Rigel Pharmaceuticals, Inc. |
Rip1 inhibitory compounds and methods for making and using the same
|
|
PE20221416A1
(es)
|
2019-09-18 |
2022-09-20 |
Novartis Ag |
Proteinas de fusion nkg2d y sus usos
|
|
PT4031547T
(pt)
|
2019-09-18 |
2024-08-27 |
Takeda Pharmaceuticals Co |
Inibidores de calicreína plasmática e utilizações dos mesmos
|
|
US11370803B2
(en)
|
2019-09-18 |
2022-06-28 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
US12516145B2
(en)
|
2019-09-30 |
2026-01-06 |
Northwestern University |
Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization
|
|
JP7795454B2
(ja)
|
2019-10-14 |
2026-01-07 |
プリンシピア バイオファーマ インコーポレイテッド |
（ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法
|
|
WO2021087076A1
(en)
|
2019-10-30 |
2021-05-06 |
Northwestern University |
Selenium-containing analogues of pheomelanin and related materials and methods of making
|
|
CN115298184B
(zh)
|
2019-11-07 |
2025-01-28 |
里格尔药品股份有限公司 |
杂环rip1抑制化合物
|
|
MX2022005795A
(es)
|
2019-11-13 |
2022-06-08 |
Rapt Therapeutics Inc |
Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas.
|
|
MX2022007441A
(es)
|
2019-12-18 |
2022-09-02 |
Calico Life Sciences Llc |
Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
|
|
AU2021209884A1
(en)
|
2020-01-22 |
2022-09-15 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
JP7767301B2
(ja)
|
2020-04-15 |
2025-11-11 |
ピラミッド バイオサイエンシズ インコーポレイテッド |
チロシン受容体キナーゼ阻害剤を調製する方法
|
|
US12240813B2
(en)
|
2020-05-19 |
2025-03-04 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
|
GB202008919D0
(en)
*
|
2020-06-11 |
2020-07-29 |
Univ Birmingham |
Polysaccharide conpositions and therapeutic gels
|
|
KR20260044248A
(ko)
|
2020-08-18 |
2026-04-01 |
사이빈 아이알엘 리미티드 |
치료 펜에틸아민 조성물 및 사용 방법
|
|
CA3194653A1
(en)
|
2020-10-02 |
2022-04-07 |
Mitokinin, Inc. |
Compositions and methods of treating kidney disease and fibrosis
|
|
EP4237421A4
(en)
|
2020-11-02 |
2024-11-06 |
Trethera Corporation |
CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND THEIR USES
|
|
EP4247340A4
(en)
|
2020-11-18 |
2024-10-02 |
Bexson Biomedical, Inc. |
COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
|
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
|
JP2024510503A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレイン阻害剤
|
|
CN117396473A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的咪唑并吡啶基抑制剂
|
|
CN117396469A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的抑制剂
|
|
JP2024510504A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレインの多環式インヒビター
|
|
WO2022197758A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl inhibitors of plasma kallikrein
|
|
CN117479941A
(zh)
|
2021-04-13 |
2024-01-30 |
帕珀莱恩医疗公司 |
毒蕈碱型乙酰胆碱m1受体拮抗剂的结晶化合物
|
|
CA3244130A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
PHENETYLAMINE DERIVATIVES, COMPOSITIONS AND METHODS OF USE
|
|
KR20240153566A
(ko)
|
2022-02-15 |
2024-10-23 |
사이빈 아이알엘 리미티드 |
치료적 펜에틸아민 조성물, 및 사용 방법
|
|
US12384775B2
(en)
|
2022-03-23 |
2025-08-12 |
Rigel Pharmaceuticals, Inc. |
Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors
|
|
WO2023192479A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
|
CN119585256A
(zh)
|
2022-04-06 |
2025-03-07 |
拉普特医疗公司 |
趋化因子受体调节剂及其用途
|
|
CN114504550B
(zh)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
一种包含甲硝唑的眼用凝胶及其制备方法
|
|
JP2025522296A
(ja)
|
2022-05-25 |
2025-07-15 |
レヴォリューション・メディスンズ，インコーポレイテッド |
ｍＴＯＲ阻害剤によりがんを処置する方法
|
|
US12377036B2
(en)
|
2022-06-21 |
2025-08-05 |
Northwestern University |
Melanin hair dye with thickeners
|
|
TW202517627A
(zh)
|
2023-07-12 |
2025-05-01 |
美商瑞佩特治療公司 |
Ｃ－ｃ趨化因子受體４型拮抗劑的結晶型及其用途
|
|
WO2025015189A1
(en)
|
2023-07-13 |
2025-01-16 |
Comanche Biopharma Corp. |
Formulations of nucleic acid compounds and uses thereof
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
WO2025068803A1
(en)
|
2023-09-26 |
2025-04-03 |
Astrazeneca Ab |
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
EP4623919A1
(en)
|
2024-03-28 |
2025-10-01 |
Marinomed Biotech AG |
Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions
|
|
WO2026022243A1
(en)
|
2024-07-23 |
2026-01-29 |
The Trustees Of The University Of Pennsylvania |
Combination of a gsk-3 inhibitor and a lsd-1 inhibitor for use in the treatment of cancer
|